Program
HS-20136-2
A development code. Also written as “HS-20136-2 injection”.
In Hansoh Pharmaceutical Group's pipeline, T2DM, weight
. Its studies are mostly in Obesity, led by Hansoh Pharmaceutical Group.
Furthest: phase 1, since Mar 12, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 22 open or running | phase 1since Mar 12, 2026 | Mar 12, 2026 | Dec 31, 2026phase 1 · NCT07483437 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20136-2 (T2DM, weight)
, phase 1, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 12, 2026First study: phase 1 study in HealthyFirst studyNCT07483437 · 38 planned · Australia
- Jul 16, 2026Phase 1 study in ObesityNCT07716241 · 92 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in HealthyNCT07483437
- May 14, 2027Primary completion: phase 1 study in ObesityNCT07716241
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“T2DM, weight”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07716241Obesity · China | 1 | Not yet recruiting | May 14, 2027 | 92 |
| NCT07483437Healthy · Australia | 1 | Not yet recruiting | Dec 31, 2026 | 38 |
How it is read
Names in the registry
- “HS-20136-2”, 2 entries
- “HS-20136-2 injection”, 1 entry
Codes read as this program: HS201362.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.